Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
17,519
Total Claims
$7.4M
Drug Cost
553
Beneficiaries
$13K
Cost/Patient
Risk Score Breakdown 28/100
Score components are additive. Read full methodology
Peer Comparison vs. 106,889 Family Practice providers
-66%
Opioid rate vs peers
0.9% vs 2.6% avg
+1158%
Cost per patient vs peers
$13K vs $1,068 avg
+169%
Brand preference vs peers
24.2% vs 9.0% avg
⚠️ This provider has metrics more than 3 standard deviations above their specialty average in one or more categories.
⚠️ Opioid + Benzodiazepine Co-Prescriber
This provider prescribes both opioids and benzodiazepines. The FDA has issued a Black Box Warning about the life-threatening risks of concurrent use.
🔎 Data Overview
Cost per patient is 1158% above the specialty average. Extreme cost outliers may indicate prescribing of unnecessarily expensive brand-name drugs or inappropriate drug utilization.
This provider co-prescribes opioids and benzodiazepines — a combination carrying an FDA Black Box Warning due to increased risk of respiratory depression and death. While sometimes clinically necessary, this combination requires careful justification.
Insights generated from CMS data analysis. Statistical patterns are not accusations — always consider clinical context.
Opioid Prescribing
0.9%
Opioid Rate
153
Opioid Claims
$1,694
Opioid Cost
—
Long-Acting Rate
Brand vs Generic
Brand: 4,024 claims · $4.6M
Generic: 12,628 claims · $2.8M
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Metformin Hcl | 161 | $567K |
| Omeprazole/Sodium Bicarbonate | 175 | $407K |
| Dulaglutide | 205 | $406K |
| Sitagliptin Phos/Metformin Hcl | 287 | $404K |
| Semaglutide | 199 | $340K |
| Empagliflozin | 155 | $231K |
| Lactulose | 53 | $226K |
| Dapagliflozin Propanediol | 164 | $201K |
| Cinacalcet Hcl | 71 | $200K |
| Sitagliptin Phosphate | 149 | $197K |
| Diclofenac Sodium | 397 | $196K |
| Diclofenac Potassium | 69 | $180K |
| Rifaximin | 32 | $144K |
| Insulin Aspart | 152 | $143K |
| Naproxen/Esomeprazole Mag | 74 | $135K |
Prescribing Profile
Patient Profile
70
Avg Age
40%
Female
1.25
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data